Bio-waiver : Recent Developments
Transcript of Bio-waiver : Recent Developments
![Page 1: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/1.jpg)
Bio-waiver : Recent Developments
Dr. V. Venkateswarlu Managing Director Neuheit Pharma Technologies Pvt Ltd HYDERABAD – INDIA www.neuheitpharma.com
BioAsia 2016 : Hyderabad
![Page 2: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/2.jpg)
2
Role of Regulatory Agency
Safety: One time assessment with dossier mainly BE
Efficacy: One time assessment with dossier mainly BE
Quality: Continuous monitoring to the end of the life of the product
![Page 3: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/3.jpg)
3
BIOEQUIVALENCE METHODS
In-Vitro BE
In-Vivo BE
![Page 4: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/4.jpg)
4
In-Vitro BE
Cholestyramine powder: Bile acids salts binding studies by in-vitro methods
Sevelamer carbonate: Phosphate binding studies by in-vitro methods
In-vitro equivalence as a pre-requisite for in-vivo BE studies: Mesalamine, inhalation products, DPI etc.,
![Page 5: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/5.jpg)
5
In-Vivo BE
Pharmacokinetic Study
Pharmacodynamic Study
Clinical Study
![Page 6: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/6.jpg)
6
US FDA
• Guidance for Industry: “Waiver of in vivo bio-equivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on a Biopharmaceutics Classification System” (2000)
EU
• “Note for Guidance on the Investigation of Bioavailability andBioequivalence” CPMP/EWP/QWP/1401/98; paragraph 5.1
WHO
• Technical Report Series No. 937, May 2006
• Annex 7: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability
• Annex 8: Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential Medicines immediate release, solid oral dosage forms
![Page 7: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/7.jpg)
7
Dosage form based
• Aqueous solutions, Dispersible tablets, miscellar injections etc.
Lower strengths
• Biowaiver for lower strengths that meet defined criteria
BCS Class based IR products
• BCS class 1 drug products in USA and BCS class 1 &3 products in EU
• WHO provided a list of drug products that are eligible for bio-waiver
DIFFERENT BIO-WAIVERS AVAILABLE
![Page 8: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/8.jpg)
8
![Page 9: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/9.jpg)
9
Ciproflaxacin in solution and dexamethasone in suspension
• US FDA issued a BE guidance involving clinical in Patients
• Complete in-vitro characterization of test and RLD convinced FDA to change BE guidance to in-vitro characterization
Reconstitution of vial with 4 ml of WFI forms suspension hence BE requirement
• Initial guidance was issued a PK study in MDS patients which is very difficult
• Q1, Q2 & Q3 concept was used to convince US FDA to change to characterization
Entry of generics into market is blocked by complex BE studies
• Innovative thinking in designing appropriate in-vitro surrogates is required
• Regulatory Agencies are helpless unless scientists come with alternative approaches for bio-waiver
![Page 10: Bio-waiver : Recent Developments](https://reader033.fdocuments.in/reader033/viewer/2022042715/626723c75a19dd4d9d66bec7/html5/thumbnails/10.jpg)